Current opinion in investigational drugs (London, England : 2000) 2005-Oct
Lasofoxifene (Pfizer).
Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
Keywords
Abstract
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaboration with Ligand, for the treatment of osteoporosis and vaginal atrophy. In August 2004, Pfizer submitted a New Drug Application to the Food and Drug Administration (FDA) seeking approval of lasofoxifene for the treatment of osteoporosis; however, in September 2005, the FDA issued a non-approvable letter.